2013-12-05 20:41:57 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Rigel Pharmaceuticals, Inc. (RIGL) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Rigel Pharmaceuticals, Inc. (RIGL). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Rigel Pharmaceuticals, Inc. investor.
Report Summary: Rigel Pharmaceuticals, Inc. is a below average quality company with a neutral outlook. Rigel Pharmaceuticals, Inc. has strong business growth and is run by inefficient management. The trend in Rigel Pharmaceuticals, Inc. fair value exchange rate against its closest rated-competitor, Depomed Inc, has been depreciating over the past 2 weeks. When compared to its closest competitor, Rigel Pharmaceuticals, Inc. shows similar overvaluation and is equally likely to underperform the market.
The report breaks down the Total StockMark into its three
components - business, management and price, performing an in-depth analysis of Rigel Pharmaceuticals, Inc. for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.